These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2767112)

  • 21. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer.
    Weinerman B; Eisenhauer E; Stewart D; Mertens W; Tannock I; Venner P; Spaulding R
    Ann Oncol; 1992 Jan; 3(1):83-4. PubMed ID: 1606075
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II study of navelbine in advanced renal cell carcinoma.
    Canobbio L; Boccardo F; Guarneri D; Calabria C; Decensi A; Curotto A; Martorana G; Giuliani L
    Eur J Cancer; 1991; 27(6):804-5. PubMed ID: 1829928
    [No Abstract]   [Full Text] [Related]  

  • 23. Chemotherapy of advanced renal cell carcinoma with vinblastine and CCNU.
    Merrin C; Mittelman A; Fanous N; Walsman Z; Murphy GP
    J Urol; 1975 Jan; 113(1):21-3. PubMed ID: 1113389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program.
    Sternberg CN; Yagoda A; Scher H; Bosl G; Dershaw D; Rosado K; Houston C; Rosenbluth R; Vinciguerra V; Boselli B
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):753-4. PubMed ID: 2523810
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II study of pyrazoloacridine in metastatic renal cell carcinoma.
    Kuebler JP; King GW; Triozzi P; Moore T; Kraut EH
    Invest New Drugs; 2001; 19(4):327-8. PubMed ID: 11561693
    [No Abstract]   [Full Text] [Related]  

  • 26. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.
    Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z
    J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II evaluation of piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study.
    Allen A; Wolf M; Crawford ED; Davis MP; Natale RB; Barnett ML
    Invest New Drugs; 1992 Jul; 10(2):129-32. PubMed ID: 1500267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.
    Scher HI; Yagoda A; Ahmed T; Budman D; Sordillo P; Watson RC
    Cancer Chemother Pharmacol; 1985; 14(1):79-80. PubMed ID: 3855289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I-II trial of gallium nitrate for advanced hypernephroma.
    Schwartz S; Yagoda A
    Anticancer Res; 1984; 4(4-5):317-8. PubMed ID: 6486736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vindesine in advanced renal cancer. A study of the EORTC Genito-urinary Tract Cancer Cooperative Group.
    Fosså SD; Denis L; van Oosterom AT; de Pauw M; Stoter G
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):473-5. PubMed ID: 6305668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of cystemustine in advanced renal cancer.
    Chauvergne J; Kerbrat P; Adenis A; Chollet P; Fargeot P; Pujade-Lauraine E; Dieras V; Madelmont JC; Lentz MA; Toulouse C
    Eur J Cancer; 1995; 31A(1):130-1. PubMed ID: 7695969
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
    Weinerman BH; Eisenhauer EA; Besner JG; Coppin CM; Stewart D; Band PR
    Cancer Treat Rep; 1986 Jun; 70(6):751-4. PubMed ID: 3524824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983-1988.
    Yagoda A
    Prog Clin Biol Res; 1990; 350():227-41. PubMed ID: 2201045
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma.
    Piot G; Droz JP; Theodore C; Ghosn M; Rouëssé J; Amiel JL
    Oncology; 1988; 45(5):371-2. PubMed ID: 3412745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group.
    van Oosterom AT; Fosså SD; Mulder JH; Calciati A; de Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1013-4. PubMed ID: 4065174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The European Organization for Research and Treatment of Cancer (EORTC) trials of new agents for advanced non-small cell lung cancer.
    Giaccone G
    Semin Oncol; 1988 Dec; 15(6 Suppl 7):46-8. PubMed ID: 2851178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I-II clinical trial with mitoclomine (NSC-114575) in chronic lymphocytic leukemia.
    Longeval E; Ganglji D; Stryckmans P; Kenis Y
    Cancer Chemother Rep; 1975; 59(6):1173-5. PubMed ID: 769961
    [No Abstract]   [Full Text] [Related]  

  • 38. [Preliminary results of 10 patients with advanced prostatic neoplasm treated with estracyt].
    de Leval J; Petit R; Bouffioux C
    Acta Urol Belg; 1974 Jul; 42(3):326-35. PubMed ID: 4440596
    [No Abstract]   [Full Text] [Related]  

  • 39. [1st experiences in the treatment of ovarian tumors with Peptichemio].
    Natale N; Mangioni C; Remotti G
    Minerva Med; 1974 May; 65(33):1805-10. PubMed ID: 4367233
    [No Abstract]   [Full Text] [Related]  

  • 40. Relationship between the pharmacokinetics and toxicity of mitozolomide.
    Kerr DJ; Slack JA; Secrett P; Stevens MF; Blackledge GR; Bradley C; Kaye SB
    Cancer Chemother Pharmacol; 1990; 25(5):352-4. PubMed ID: 2306796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.